Literature DB >> 33452286

Prevalence of different comorbidities in chronic obstructive pulmonary disease among Shahrekord PERSIAN cohort study in southwest Iran.

Fatemeh Zeynab Kiani1, Ali Ahmadi2,3.   

Abstract

Comorbidities are common in chronic obstructive pulmonary disease (COPD) patients. This study was conducted to determine the prevalence of common comorbidities in patients with COPD compared with people without COPD. This cross-sectional, population-based study was performed on 6961 adults aged 35-70 years enrolled in the Shahrekord PERSIAN cohort study. Data (demographic and clinical characteristics, comorbidities, anthropometric and blood pressure measurements, laboratory, and spirometry tests) collection was performed according to the cohort protocol from 2015 to 2019. In the present study, 215 (3.1%) patients were diagnosed with COPD and 1753 (25.18%) ones with restrictive lung patterns. The mean age of COPD patients was 52.5 ± 9.76 years. 55.8% of patients were male, 17.7% were current smokers and 12.1% had a history of smoking or were former smokers. 5.6% of patients had no comorbidity and 94.5% had at least one comorbidity. The most common comorbidities in COPD patients were dyslipidemia (70.2%), hypertension (30.2%), metabolic syndrome (22.8%), and diabetes (16.7%). The most common comorbidities in individuals with a restrictive spirometry pattern were dyslipidemia (68.9%), metabolic syndrome (27.2%), hypertension (26.1%), depression (17.6%), and fatty liver (15.5%). The logistic regression analysis with 95% confidence interval (95%CI) of odds ratio (OR) showed that comorbidities of chronic lung diseases (OR = 2.12, 95% CI 1.30-3.44), diabetes (OR = 1.54, 95%CI 1.03-2.29), cardiovascular disease (OR = 1.52, 95%CI 1.17-2.43), and hypertension (OR = 1.4, 95%CI 1.02-1.99) were more likely to occur in COPD patients than in healthy individuals. Knowing these prevalence rates and related information provides new insights on comorbidities to reduce disease burden and develop preventive interventions and to regulate health care resources to meet the needs of patients in primary health care.

Entities:  

Year:  2021        PMID: 33452286      PMCID: PMC7810834          DOI: 10.1038/s41598-020-79707-y

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  44 in total

1.  Standardisation of spirometry.

Authors:  M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger
Journal:  Eur Respir J       Date:  2005-08       Impact factor: 16.671

2.  Costly comorbidities of COPD: the ignored side of the coin?

Authors:  Job F M van Boven
Journal:  Eur Respir J       Date:  2017-07-27       Impact factor: 16.671

3.  Pattern of Cardiovascular Comorbidity in COPD in a Country with Low-smoking Prevalence: Results from Two-population-based Cohorts from Sweden.

Authors:  Berne Eriksson; Helena Backman; Linda Ekerljung; Malin Axelsson; Anne Lindberg; Eva Rönmark; Bo Lundbäck
Journal:  COPD       Date:  2018-11-26       Impact factor: 2.409

4.  Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD.

Authors:  Bianca Beghé; Alessia Verduri; Mihai Roca; Leonardo M Fabbri
Journal:  Eur Respir J       Date:  2013-04       Impact factor: 16.671

5.  Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population.

Authors:  Peter Lange; Jacob Louis Marott; Jørgen Vestbo; Kim Rose Olsen; Truls Sylvan Ingebrigtsen; Morten Dahl; Børge Grønne Nordestgaard
Journal:  Am J Respir Crit Care Med       Date:  2012-09-20       Impact factor: 21.405

6.  Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study.

Authors:  Ana Maria B Menezes; Rogelio Perez-Padilla; José Roberto B Jardim; Adriana Muiño; Maria Victorina Lopez; Gonzalo Valdivia; Maria Montes de Oca; Carlos Talamo; Pedro C Hallal; Cesar G Victora
Journal:  Lancet       Date:  2005-11-26       Impact factor: 79.321

7.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.

Authors:  Claus F Vogelmeier; Gerard J Criner; Fernando J Martinez; Antonio Anzueto; Peter J Barnes; Jean Bourbeau; Bartolome R Celli; Rongchang Chen; Marc Decramer; Leonardo M Fabbri; Peter Frith; David M G Halpin; M Victorina López Varela; Masaharu Nishimura; Nicolas Roche; Roberto Rodriguez-Roisin; Don D Sin; Dave Singh; Robert Stockley; Jørgen Vestbo; Jadwiga A Wedzicha; Alvar Agustí
Journal:  Am J Respir Crit Care Med       Date:  2017-03-01       Impact factor: 21.405

8.  The prevalence of COPD co-morbidities in Serbia: results of a national survey.

Authors:  Ljudmila M Nagorni-Obradovic; Dejana S Vukovic
Journal:  NPJ Prim Care Respir Med       Date:  2014-06-12       Impact factor: 2.871

Review 9.  Prevalence of comorbidities in chronic obstructive pulmonary disease patients: A meta-analysis.

Authors:  Hong-Lei Yin; Shi-Qi Yin; Qing-Yan Lin; Ying Xu; Hong-Wei Xu; Tao Liu
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

10.  Influence of country-level differences on COPD prevalence.

Authors:  Shawn D Aaron; Andrea S Gershon; Yuan Gao; Jenna Yang; G A Whitmore
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-09-19
View more
  1 in total

Review 1.  Promising Expectations for Pneumococcal Vaccination during COVID-19.

Authors:  Hyobin Im; Jinhui Ser; Uk Sim; Hoonsung Cho
Journal:  Vaccines (Basel)       Date:  2021-12-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.